Blinatumomab attaches to T cells (top left) and cancer cells (top right), enabling T cells to find and destroy cancer cells (bottom right). During this process, T cells are activated, creating more killer T cells (bottom left).
Credit: Drug Safety, May 2019. https://doi.org/10.1007/s40264-018-0760-1. CC BY-NC 4.0.